טוען...
Efficacy and safety of tofacitinib in patients with active rheumatoid arthritis: review of key Phase 2 studies
Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Here, the safety and efficacy data from five Phase 2 studies of tofacitinib in patients with RA are summarized. Tofacitinib 1–30 mg twice daily was investigated, as monotherapy and in combination with metho...
שמור ב:
| הוצא לאור ב: | Int J Rheum Dis |
|---|---|
| Main Authors: | , , , , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
John Wiley and Sons Inc.
2016
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5396326/ https://ncbi.nlm.nih.gov/pubmed/27451980 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1756-185X.12901 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|